BLACK WEEKSBočice −15% · kompleti −10% · ostalo −5%s kodomBesplatna dostava u Njemačkoj od 200 €

Ova je stranica automatski prevedena i može sadržavati pogreške. Jeste li izvorni govornik? Rado ćemo primiti vaše povratne informacije i ispravke.Pošaljite povratne informacije

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), fotografija proizvoda

Laboratorijsko izvješće

PDF
Testirano
Testirano
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Laboratorij
Analiza Białek
Datum
October 2026
Rezultat
20.34 mg per tablet (20 mg label)
Br. narudžbe
Lozinka

Neovisno testirano, može se provjeriti lozinkom izravno u laboratoriju.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Narudžba

Jedinična cijena - Besplatna dostava u Njemačkoj iznad 200 € tijekom akcije Black Weeks
  • DHL s praćenjem
  • Diskretno pakiranje

4.6 od 5 na Trustpilotu73 recenzija

Na prvi pogled

Tamoxifen (Nolvadex) u brojkama

Ključni podaci iz našeg leksikona.

Cijeli članak u leksikonu
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Znanje

Sve o Tamoxifen (Nolvadex)

FAQ

Česta pitanja

Izvori za svaki odgovor: članak u leksikonu

Imate još pitanja?

Pišite nam, naš tim će vam pomoći.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Usporedbe

Kako se uspoređuje

Povezano

Srodni proizvodi